(0.21%) 5 142.50 points
(0.17%) 38 505 points
(0.30%) 17 899 points
(-0.31%) $83.59
(1.82%) $1.958
(0.17%) $2 351.10
(0.57%) $27.69
(0.94%) $930.75
(-0.09%) $0.934
(-0.21%) $11.00
(-0.20%) $0.799
(1.29%) $93.06
Live Chart Being Loaded With Signals
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide...
Stats | |
---|---|
本日の出来高 | 341.00 |
平均出来高 | 3 218.00 |
時価総額 | 329.08B |
EPS | €0 ( 2024-04-15 ) |
次の収益日 | ( €0 ) 2024-07-16 |
Last Dividend | €1.190 ( 2023-08-25 ) |
Next Dividend | €0 ( N/A ) |
P/E | 19.71 |
ATR14 | €0.113 (0.08%) |
ボリューム 相関
Johnson & Johnson 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Johnson & Johnson 相関 - 通貨/商品
Johnson & Johnson 財務諸表
Annual | 2023 |
収益: | €85.16B |
総利益: | €58.61B (68.82 %) |
EPS: | €13.88 |
FY | 2023 |
収益: | €85.16B |
総利益: | €58.61B (68.82 %) |
EPS: | €13.88 |
FY | 2022 |
収益: | €94.94B |
総利益: | €63.85B (67.26 %) |
EPS: | €6.86 |
FY | 2021 |
収益: | €93.78B |
総利益: | €63.92B (68.16 %) |
EPS: | €7.93 |
Financial Reports:
No articles found.
Johnson & Johnson Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€1.130 (N/A) |
€1.130 (N/A) |
€1.130 (N/A) |
€1.190 (N/A) |
€1.190 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.415 | 2008-02-22 |
Last Dividend | €1.190 | 2023-08-25 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 65 | -- |
Total Paid Out | €56.18 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.59 | -- |
Div. Sustainability Score | 3.76 | |
Div.Growth Potential Score | 5.82 | |
Div. Directional Score | 4.79 | -- |
Year | Amount | Yield |
---|
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LOM.DE | Ex Dividend Knight | 2023-08-31 | Quarterly | 0 | 0.00% | |
2GB.DE | Ex Dividend Junior | 2023-06-14 | Annually | 0 | 0.00% | |
V6C.DE | Ex Dividend Junior | 2023-06-01 | Annually | 0 | 0.00% | |
ELG.DE | Ex Dividend Knight | 2023-05-11 | Annually | 0 | 0.00% | |
NTH.DE | Ex Dividend Knight | 2023-08-25 | Quarterly | 0 | 0.00% | |
AEIN.DE | Ex Dividend Knight | 2023-06-14 | Annually | 0 | 0.00% | |
GOB.DE | Ex Dividend Knight | 2023-06-12 | Sporadic | 0 | 0.00% | |
PSQ.F | Ex Dividend Knight | 2023-08-23 | Semi-Annually | 0 | 0.00% | |
BLQA.DE | Ex Dividend Knight | 2023-09-07 | Quarterly | 0 | 0.00% | |
INH.DE | Ex Dividend Knight | 2023-05-18 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.453 | 1.500 | 0.949 | 1.424 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.572 | 1.500 | 4.76 | 7.14 | [0.1 - 1] |
payoutRatioTTM | 0.218 | -1.000 | 7.82 | -7.82 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 44.51 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 8.03 | 2.00 | 7.32 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 6.32 | 2.00 | 6.84 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.687 | 1.000 | 1.890 | 1.890 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.273 | 1.000 | 6.54 | 6.54 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 3.76 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 8.83 | 1.000 | 9.21 | 0 | [1 - 100] |
returnOnEquityTTM | 0.572 | 2.50 | 6.63 | 7.14 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 6.32 | 2.00 | 7.89 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.23 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 8.03 | 2.00 | 7.32 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.218 | 1.500 | 7.82 | -7.82 | [0 - 1] |
pegRatioTTM | -0.303 | 1.500 | -5.35 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.218 | 1.000 | 7.05 | 0 | [0.1 - 0.5] |
Total Score | 5.82 |
Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。